Evolus, Inc. (NASDAQ: EOLS) recently announced the departure of its Chief Financial Officer, Sandra Beaver, effective June 13, 2025. Beaver is leaving the company to assume the same position at a private mental health and wellness technology company. However, her departure is stated not to be the result of any disagreements related to the company's operations, policies, practices, accounting principles, financial statements, or disclosures.
Evolus' President and CEO, David Moatazedi, expressed gratitude for Beaver's contributions and highlighted the company's recent accomplishments, including the launch of a second product line, record revenues, a fortified balance sheet, and positioning for profitability.
The company has initiated a search for Beaver's successor, and in the interim, Evolus' experienced finance team will continue to lead the accounting, finance, and investor relations functions to ensure a smooth transition.
Evolus, Inc. is described as a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. The company's flagship products include Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels.
The press release did not include specific financial metrics or comparative figures from the previous period. Following these announcements, the company's shares moved 1.6%, and are now trading at a price of $9.835. If you want to know more, read the company's complete 8-K report here.
